Daniel Miotto Dupont

Dr. Daniel Miotto Dupont


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MDMichelle K.V. Durand
Michelle K.V. Durand
JBJulie S. Bødker
Julie S. Bødker
ACAnni Christensen
Anni Christensen
DDDaniel Miotto Dupont
Daniel Miotto Dupont
MHMartin Hansen
Martin Hansen
PAPeter A. Andreasen
Peter A. Andreasen
Summary: In recent decades, evidence has been accumulating showing the important role of urokinase-type plasminogen activator (uPA) in growth, invasion, and metastasis of malignant tumours. The evidence comes from results with animal tumour models and from the observation that a high level of uPA in human tumours is associated with a poor patient prognosis. It therefore initially came as a surprise that a high tumour level of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) is also associated with a poor prognosis, the PAI-1 level in fact being one of the most informative biochemical prognostic markers. We review here recent investigations into the possible tumour biological role of PAI-1, performed by animal tumour models, histological examination of human tumours, and new knowledge about the molecular interactions of PAI-1 possibly underlying its tumour biological functions. The exact tumour biological functions of PAI-1 remain uncertain but PAI-1 seems to be multifunctional as PAI-1 is expressed by multiple cell types and has multiple molecular interactions. The potential utilisation of PAI-1 as a target for anti-cancer therapy depends on further mapping of these functions.

1 January 2009 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Closed access
DDDaniel Miotto Dupont
Daniel Miotto Dupont
JMJeppe Buur Madsen
Jeppe Buur Madsen
TKThomas Kristensen
Thomas Kristensen
JBJulie Stove Bodker
Julie Stove Bodker
GBGrant Ellsworth Blouse
Grant Ellsworth Blouse
PAPeter Andre Andreasen
Peter Andre Andreasen
PAI-1 is a Mr ~50,000 glycoprotein, which is the primary physiological inhibitor of the two plasminogen activators uPA and tPA. PAI-1 belongs to the serpin protein family. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. In PAI-1, this insertion can occur in the absence of the protease, resulting in generation of a so-called latent, inactive form of the protein. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family.

12 August 2011 in Small
Verified
Journal Article
Closed access
PDF file
NMNicolas Mackiewicz
Nicolas Mackiewicz
Edmond GRAVELEdmond GRAVEL
Edmond GRAVEL
AGAnikitos Garofalakis
Anikitos Garofalakis
JOJulien Ogier
Julien Ogier
JJJubi John
Jubi John
FDFrédéric Ducongé
Frédéric Ducongé

20 September 2011 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ACAgnes Cibiel
Agnes Cibiel
DDDaniel Miotto Dupont
Daniel Miotto Dupont
FDFrédéric Ducongé
Frédéric Ducongé
Aptamers are nucleic acid-based ligands identified through a process of molecular evolution named SELEX (Systematic Evolution of Ligands by Exponential enrichment). During the last 10-15 years, numerous aptamers have been developed specifically against targets present on or associated with the surface of human cells or infectious pathogens such as viruses, bacteria, fungi or parasites. Several of the aptamers have been described as potent probes, rivalling antibodies, for use in flow cytometry or microscopy. Some have also been used as drugs by inhibiting or activating functions of their targets in a manner similar to neutralizing or agonistic antibodies. Additionally, it is straightforward to conjugate aptamers to other agents without losing their affinity and they have successfully been used in vitro and in vivo to deliver drugs, siRNA, nanoparticles or contrast agents to target cells. Hence, aptamers identified against cell surface biomarkers represent a promising class of ligands. This review presents the different strategies of SELEX that have been developed to identify aptamers for cell surface-associated proteins as well as some of the methods that are used to study their binding on living cells.

20 April 2010 in Biochemistry
Verified
Journal Article
Closed access
JMJeppe B. Madsen
Jeppe B. Madsen
DDDaniel Miotto Dupont
Daniel Miotto Dupont
TAThomas B. Andersen
Thomas B. Andersen
ANAnne F. Nielsen
Anne F. Nielsen
LSLu Sang
Lu Sang
PAPeter A. Andreasen
Peter A. Andreasen

10 July 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
DDDaniel Miotto Dupont
Daniel Miotto Dupont
NLNiels Larsen
Niels Larsen
JJJan. K. Jensen
Jan. K. Jensen
PAPeter A. Andreasen
Peter A. Andreasen
JKJørgen Kjems
Jørgen Kjems
Nucleic acid aptamer selection by systematic evolution of ligands by exponential enrichment (SELEX) has shown great promise for use in the development of research tools, therapeutics and diagnostics. Typically, aptamers are identified from libraries containing up to 1016 different RNA or DNA sequences by 5–10 rounds of affinity selection towards a target of interest. Such library screenings can result in complex pools of many target-binding aptamers. New high-throughput sequencing techniques may potentially revolutionise aptamer selection by allowing quantitative assessment of the dynamic changes in the pool composition during the SELEX process and by facilitating large-scale post-SELEX characterisation. In the present study, we demonstrate how high-throughput sequencing of SELEX pools, before and after a single round of branched selection for binding to different target variants, can provide detailed information about aptamer binding sites, preferences for specific target conformations, and functional effects of the aptamers. The procedure was applied on a diverse pool of 2′-fluoropyrimidine-modified RNA enriched for aptamers specific for the serpin plasminogen activator inhibitor-1 (PAI-1) through five rounds of standard selection. The results demonstrate that it is possible to perform large-scale detailed characterisation of aptamer sequences directly in the complex pools obtained from library selection methods, thus without the need to produce individual aptamers.